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Abstract
Introduction—Determining whether hormonal contraception (HC), particularly the injectable
contraceptive depot-medroxyprogesterone acetate (DMPA), increases a woman's risk of HIV
acquisition is a priority question for public health. However, assessing the relationship between
various HC methods and HIV acquisition with observational data involves substantial analytic
design issues and challenges. Studies to date have used inconsistent approaches and generated a
body of evidence that is complex and challenging to interpret.
Methods—In January 2013, USAID and FHI 360 supported a meeting of epidemiologists,
statisticians, and content experts to develop recommendations for future observational analyses of
HC and HIV acquisition.
Results—Meeting participants generated recommendations regarding careful definition of
exposure groups; handling potential confounders, mediators, and effect modifiers; estimating and
addressing the magnitude of measurement error; using multiple methods to account for pregnancy;
and exploring the potential for differential exposure to HIV-infected partners. Advantages and
disadvantages of various statistical approaches to account for time-varying confounding and
estimating total and direct effects were also discussed.
Conclusions—Implementing these recommendations in future observational HC-HIV
acquisition analyses will enhance interpretation of existing studies and strengthen the overall
evidence base for this complex and important area.
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Introduction
Determining whether use of hormonal contraception (HC) increases a woman's risk of HIV
acquisition is a priority research question for women's health [1, 2]. HC prevents unintended
pregnancy and contributes to reductions in maternal and infant morbidity and mortality [3].
Globally, over 150 million women use HC, including oral contraceptive pills, injectable
contraceptives (depot-medroxyprogesterone acetate [DMPA], norethisterone enanthate
[NET-EN], or combined injectables), contraceptive implants, rings, patches, or
levonorgestrel-releasing intrauterine devices (IUD) [4]. In sub-Saharan Africa, nearly 60%
of HC users rely on injectable contraception [4], a highly effective, long-lasting, reversible
method which can be used discreetly and provided by community health workers [5]. Some
observational studies have raised concerns of a potentially increased risk of HIV acquisition
among users of HC, primarily DMPA, but results overall are inconsistent and study quality
varies greatly [6]. The widespread use of injectables in sub-Saharan Africa, an area of high
HIV prevalence and incidence, heightens these concerns. During a 2012 WHO technical
consultation, 75 experts reviewed all available biological, epidemiological, and modeling
data, and recommended that WHO continue to suggest no restriction on the use of any HC
method; however, they noted that condom use and other HIV preventive measures should be
strongly emphasized for women at high risk of HIV who choose progestogen-only injectable
contraception [1].
Twenty observational cohort studies published from 1991 to 2012, and conducted among a
range of populations (e.g., family planning clinic attendees, commercial sex workers,
women with HIV-1 infected partners, etc.), have used varied methodological approaches and
generated heterogeneous results [6]. At the 2012 WHO consultation, experts gave the
collective body of epidemiological evidence on HC and HIV acquisition a GRADE rating of
“low” [7-10], due in part to inconsistencies between study results. Greater consistency and
rigor in analytic approaches may allow for clearer interpretation of individual study results
and comparability across studies, strengthening the overall evidence base and improving the
GRADE rating. The complete body of evidence, including studies published since the 2012
WHO consultation [11, 12] will be reviewed at the next WHO technical consultation,
currently planned for 2014.
Formal discussion on how to improve the observational HC-HIV acquisition evidence base
has been limited. In response to the need to strengthen and harmonize HC-HIV acquisition
analytic approaches for observational data, USAID and FHI 360 supported a meeting
entitled “Best practices in analytic approaches to assess the effect of hormonal
contraception on HIV acquisition with observational data,” in Seattle, WA on January
24-25, 2013. Epidemiologists, biostatisticians, and content experts discussed
recommendations on best analytic practices for future observational analyses; this report
summarizes those discussions and presents recommendations for future analyses.
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Observational analyses to assess the HC-HIV acquisition relationship present multiple
challenges in analytic design. Below, we highlight several key challenges of conducting
these analyses and offer recommendations (summarized in Table 1) that should be
considered prior to the initiation of a primary or secondary observational analysis of HC and
HIV acquisition.
Defining HC exposure and HIV outcome
In HC-HIV acquisition analyses, the outcome of interest is HIV acquisition, the detection of
which requires repeated HIV testing. Defining HC exposure is more complex. Each HC
method induces different biological effects, therefore it is critical to disaggregate by HC
method type (e.g., pills vs. injectables vs. implants vs. IUDs), and when possible, by
formulation (e.g., DMPA vs. NET-EN, estrogen and progestin combined methods vs.
progestin-only methods, etc.) and dosage (e.g., intramuscular DMPA vs. lower-dose
subcutaneous DMPA, etc.). Some studies to date have disaggregated by HC type, and a few
have disaggregated by formulation [6]. High rates of contraceptive discontinuation and
switching [13] and imperfect adherence [14] lead to complex exposure patterns,
necessitating frequently updated, prospectively collected HC exposure data. Sensitivity
analyses can explore the impact of censoring follow-up time when women first switch their
contraceptive method. Any induced informative censoring would have to be addressed using
additional analytic approaches, such as inverse probability weighting. An additional
question is whether the exposure of interest is current exposure to HC (which most studies
have addressed) or some summary of cumulative HC exposure [15].
Defining the “no HC exposure” comparison group
To date, most studies have assessed whether a particular HC method increases HIV risk
relative to using no HC, but the composition of the “no HC” unexposed comparison group
has varied. Women not using HC may be using condoms, copper IUDs, withdrawal,
spermicides, diaphragms, sterilization, hysterectomy, traditional methods, or nothing to
prevent pregnancy (some of these women may be actively trying to become pregnant). Thus,
women not using HC may be heterogeneous with respect to any contraceptive use or non-
use, with accompanying differences in other important factors, such as coital frequency,
exposure to sexually transmitted infections (STIs), and pregnancy intention; factors which
have not always been measured in previous studies. Further, some of these methods (or lack
thereof) may magnify or dilute HIV incidence in the comparison group. For example,
women using condoms for pregnancy prevention without an HC method (who would thus be
in the “no HC” group) typically report more consistent use of condoms than women using
condoms for HIV/STI prevention (who could be in either group) [16-21]. This could induce
bias in the effect estimate if consistency of condom use over time, a challenging variable to
assess, is not adequately measured and controlled. Some studies have contained comparison
groups composed largely of women using condoms [22], while others have had few or no
condom users in the comparison group [23]. Differences in comparison groups between
studies could lead to substantial differences in effect estimates. Thus, clear descriptions of
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the composition of the comparison group, with these parameters in mind, are necessary for
cross-study comparisons.
Alternate comparison groups
In addition to comparisons of HC users versus non-HC users, future observational analyses
could compare HIV acquisition rates among women choosing various effective
contraceptive methods, (e.g., DMPA versus IUD, DMPA versus NET-EN, etc.). Such
comparisons have not been made to date, but would reframe the research question to
identifying the safest method of HC (with respect to HIV acquisition) among contracepting
women at risk of HIV infection. Many recent HIV prevention trials emphasized counseling
and on-site provision of effective contraceptive methods for participants; in these trials, most
women used HC. Thus, future analyses using these datasets may be best suited to answering
questions that compare different HC methods against each other. An advantage to this
comparison is that underlying HIV risk (as measured, for example, by report of sexual
behaviors and condom use consistency) may be similar among groups of women choosing
highly effective contraceptive methods, which would reduce potential confounding by these
factors. However, without an established understanding of baseline HIV-related risk of the
comparison for each method, interpreting risk estimates may be challenging. For example, a
null effect may indicate that neither method impacts risk, or that both methods increase or
decrease risk equally.
Confounding, time-varying confounding, mediation, and effect modification
Women who choose to use HC are different from women who do not, and these differences
may also be related to underlying risks for HIV infection. Such differences will result in
confounded estimates of the HC-HIV relationship if not appropriately controlled. In
addition, mediating factors that result from the exposure (HC) and that cause the outcome
(HIV acquisition) can also complicate analyses and the interpretation of results. Some
confounders may simultaneously act as mediators. For example, DMPA use may be
influenced by recent coital frequency, and DMPA use may also affect subsequent coital
frequency. Such variables, known as time-varying confounders, must be addressed using
appropriate analytic techniques, e.g., marginal structural models (MSM), which have been
used in some studies.[11, 24-26] Several early HC-HIV studies did not adjust for important
confounders [6], and to date, no published observational studies have assessed potential
mediation.
Since it is not always clear if certain variables (for example, coital frequency or condom
use) should be assessed as confounders, mediators, or both, it is important to consider how
each variable is included in a statistical model. Conceptual models can be used to help
specify a priori which factors are assumed to operate as potential confounders, mediators, or
both. Meeting participants drafted a simplified conceptual model (Figure 1) to illustrate
theoretical relationships between use of an HC method (exposure) and HIV acquisition
(outcome), listing multiple important potential confounders and/or mediators [27-31]. While
it was not feasible to specify one model, given uncertainty on how best to incorporate the
large number of potential variables, participants agreed which key factors to consider, and
that several time-varying factors have been demonstrated in previous studies to act
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simultaneously as confounders and mediators, including condom use, participant behavioral
risk, and primary partner risk [24]. Future analyses should consider factors shown in Figure
1, and provide a rationale if they are not included in statistical models.
Previous studies have assessed whether various factors such as age, country, or infection
with herpes simplex virus type-2 (HSV-2), could potentially act as effect modifiers of the
HC-HIV acquisition relationship, but results have been mixed. Future investigations should
explain biologically plausible mechanisms for apparent effect modification, and also
consider the potential for differential confounding across strata, which could generate
spurious effect modification [32].
Total and direct effects
The terms “total effects” and “direct effects” are used to describe relationships between an
exposure, an outcome, and other factors in the causal pathway [33, 34]. Figure 2 displays a
simplified causal diagram for one hypothesized HC-HIV relationship, suggesting condom
use as one potential mediator. In Figure 2, the “direct effect” of HC on HIV risk is not
mediated through condom use, while the “indirect effect” of HC on HIV is the mediated
pathway through condom use. In this simplified example, the “total effect” is the overall
effect of HC use on HIV acquisition (after controlling for confounding factors) of the direct
and indirect effects combined. All three types of effects – direct, indirect, and total – are
assumed to be free of confounding.
At the meeting, opinions differed as to whether estimating a total effect or a direct effect of
HC not mediated by behavioral factors (informally referred to as a “biological” effect)
would be more relevant to the policy agenda. Total effects are useful when the interest is in
the overall effect of an HC method (including consequent effects of HC on mediators) on
HIV risk, while the direct effect attempts to isolate the effect of a HC method on HIV risk
not mediated by other factors. The direct effect may be more generalizable if the biological
response to HC differs less than socially, culturally, and behaviorally mediated responses.
While direct effects may be valuable, they may be difficult to obtain given challenges in
accurately measuring confounding and mediating factors, the requisite additional
assumptions required for their estimation, and potential loss of statistical precision.[34, 35]
Regardless of the effect estimated, it will continue to be important to prioritize novel
programs to increase condom use alongside highly effective contraceptive methods, develop
multipurpose prevention technologies,[36, 37] and expand contraceptive method options.
However, if DMPA is found to increase risk of HIV, and a large portion of that effect is
“biological” (and of substantial magnitude) [38], then it would be particularly crucial to
enhance access to alternative safe, acceptable highly effective contraceptive methods,
particularly in areas where both DMPA use and HIV prevalence is high. Such an effort
might be lower priority if the total effect of HC on HIV were due to behavioral factors rather
than (for example) physiological changes caused on the body by HC. Future studies should
be clear about the effect being estimated (total or direct; and if direct, with respect to what
factors), and consider estimating both where possible.
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Analytic challenges & considerations
Measurement error and missing data
Self-reported data about sexual behavior and HC use are subject to biases, including
misreporting, recall, and social desirability. In addition, data on these important factors may
be intermittently missing as a result of unattended follow-up visits. Methods to address
measurement error and missing data, minimize bias and estimate its magnitude and
direction, or examine the robustness of primary analytic results may help to interpret
findings from observational analyses. For example, to examine the accuracy of self-reported
condom use, investigators can compare HIV (or other STI) acquisition rates or pregnancy
rates between women who report consistently using condoms and those who do not. HIV
incidence rates among consistent condom users are expected to be lower than women who
never use condoms. If female genital specimens are available, biologic markers of
unprotected intercourse (for example, prostate specific antigen (PSA) or Y-chromosome
testing) could provide a biomarker of this behavior to help to estimate over-reporting of
condom use among women who report recent sex [39]. Investigators can also conduct
sensitivity analyses among individuals who report no condom use (by censoring at initiation
of condom use, though this may be informative), as these individuals may theoretically be
less vulnerable to social desirability bias [40, 41]; similarly, studies that include a small
proportion of condom users may be less prone to condom over-reporting. To examine the
accuracy of self-reported HC use, pregnancy rates among women reporting different types
of contraceptive methods can be compared. Pregnancy rates would be expected to be higher
among women using more user-dependent methods (condoms, oral contraceptives)
compared to user-independent methods (injections, implants, IUDs). If these trends hold,
they are an indication that self-reported data are accurate on an aggregate level. Other
sensitivity analyses may be possible to examine the extent of inaccuracy in other potentially
confounding factors.
If confounding (including residual confounding due to misreporting) is suspected to impact
the effect estimates, it is important to provide information on the likely magnitude and
direction of bias. One recent mathematical modeling example assessed the magnitude of
differential misreporting required to generate a spurious doubling of HIV risk with
injectable HC use in a recent HC-HIV acquisition study [26], and suggested that
underreporting of condom use would need to be unrealistically large to have generated the
reported effect estimate if condom use were the only confounder.[42]
Accounting for pregnancy
Previous studies have addressed pregnancy in several ways: no reported adjustment for
incident pregnancy, censoring at pregnancy, and treatment of pregnancy as a time-varying
confounder. HC prevents pregnancy, and pregnancy has been associated with an increased
risk of HIV acquisition in some, but not all, observational studies [22, 23, 43, 44]. Yet even
if pregnancy acts as a confounder of the HC-HIV relationship, adjusting for pregnancy may
be problematic, since becoming pregnant makes a woman “ineligible” for HC use, thereby
violating the positivity assumption which requires that there are both exposed and
unexposed participants at all values of the confounder(s) [45]. The meeting's participants
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concluded that the most appropriate method to address pregnancy should depend on the
question being asked. If analytic interest is in direct effects not influenced by pregnancy,
then censoring at pregnancy may be appropriate, although such censoring may be
informative. If interest is in the total effect, then pregnancy (as part of that total effect)
should not be “controlled away” (although confounding by pregnancy status may still be an
issue). The optimal approaches to address pregnancy in HC-HIV analyses require further
study. At present, implementation of various approaches for pregnancy is recommended in
order to gauge the range of results when different approaches are employed.
Accounting for HIV exposure and partner risk
A substantial proportion of women participating in HIV prevention studies may never be
exposed to HIV [6, 46]. Heterogeneity in HIV exposure risk may introduce bias if HIV
exposure is linked to decisions regarding contraceptive method choice. If HIV exposure
differs by HC method, this could impact results. Characterization of the level of HIV
exposure could be achieved by assessing serodiscordant couples (ideally with information
on male partner HIV viral load), by testing of female genital samples for viral HIV-1 DNA
from male partners, or by testing partners for HIV. In the absence of data on partner risk,
composite variables of sociodemographic factors related to partner risk could be considered,
but proxy measures of partner risk may have limited utility [47] and should be validated.
Further research would be useful for improving our understanding of HIV exposure in
different populations, and whether HC use is associated with the likelihood of HIV
exposure.
Statistical model considerations in the presence of time-dependent
confounding
The majority of prospective HC-HIV studies have used Cox proportional hazards regression
models, which can induce bias in the presence of time-varying confounders that are also
mediating factors [48-50]. For example, if coital frequency (which changes over time)
affects both use of DMPA and HIV acquisition risk (and so is a confounder), but is also
affected by DMPA use (and so is also a mediator), then traditional regression approaches
such as Cox models can give a biased effect estimate. This may happen even if there is no
uncontrolled confounding (see also previous section entitled Confounding, time-varying
confounding, mediation, and effect modification). Several alternative methods can estimate
unbiased effects in such data (subject to assumptions including no uncontrolled
confounding): the parametric g-formula [51-53], g-estimation of structural nested models
[54, 55], and marginal structural models (MSM) [48, 49] fit with inverse probability weights
(IPW) [56]. Collectively, these are referred to as “the g-methods.” These methods can also
estimate either total or direct effects in specific situations in which traditional regression
approaches cannot [34].
Of these methods, MSM fit with IPW are technically easiest to implement, and several
recent HC-HIV analyses have used this approach [11, 24-26, 57]. In contrast to MSM,
neither g-estimation nor the parametric g-formula has been widely implemented. The
parametric g-formula is technically and computationally intensive, and has the disadvantage
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of requiring numerous parametric assumptions. A notable advantage of this approach,
however, is that the assumptions of the parametric g-formula complement those of IPW
MSM [52]: the sets of relations modeled are complementary between the two methods. As
such, the g-formula may make a good sensitivity analysis for HC-HIV acquisition analyses.
More statistical details regarding MSM [48, 49, 58] and the g-formula [51, 53] can be found
elsewhere.
Despite theoretical advantages of g-methods (including MSMs), over traditional regression
approaches, if strong time-dependent confounding is absent from a dataset being used to
estimate an HC-HIV acquisition relationship, then g-methods are unlikely to provide
markedly different results from traditional methods [26]. The absence of strong time-
dependent confounding could occur because current HC use has little or no effect on the
mediator/confounder or because the mediator/confounder has little effect on the probability
of future exposure to HC use; such assumptions could be tested prior to employing g-
methods [59].
Theory shows that g-methods are the more statistically appropriate methods for longitudinal
HC-HIV acquisition analyses. However, it is critical to note that their use does not
guarantee an unbiased answer. The g-methods, like all statistical approaches, require a
number of assumptions to be met. The aforementioned measurement issues, such as the
failure to measure all relevant confounders or to appropriately account for measurement
error, are likely to yield biased estimates from any analytic approach, including the g-
methods. In addition, there are numerous practical and technical issues with the
implementation of g-methods, and MSM specifically, that are not currently addressed in the
epidemiologic or biostatistical literature. Descriptions of these challenges and suggested
solutions would be helpful in framing future HC-HIV acquisition analyses (as well as other
subjects).
Conclusions
Despite the challenges described here, future secondary analyses using existing high-quality
datasets could inform our understanding of the HC-HIV acquisition relationship. Several
analyses are on the horizon, including those from both individual and combined datasets.
Furthermore, new HIV prevention studies that will collect information on contraceptive use
will provide additional relevant data (including trials of tenofovir gel and a dapivirine-
containing vaginal ring). Future studies that do not address the issues listed in Table 1 are
less likely to meaningfully contribute to the existing evidence base.
This paper aims to contribute to an evolving discussion on observational HC-HIV
acquisition evidence. We hope to spur conversations that build upon the recommendations in
this paper. Methodological progress on addressing pregnancy in HC-HIV acquisition
analyses is needed, as is dialogue with investigators conducting longitudinal cohort studies
in areas of high HIV incidence, to ensure inclusion of relevant data collection tools into
ongoing trials. Additionally, in light of a growing evidence base, discussions on how best to
systematically assess this complex body of literature should also continue. We hope our
recommendations might assist in interpreting existing studies; by outlining major challenges
Polis et al. Page 8






















of observational HC-HIV analyses, systematic assessment across studies is more
straightforward. A recent HC-HIV acquisition systematic review specified minimum quality
criteria for more in-depth analysis of higher quality studies [6]. As the evidence base
continues to change and improve, these criteria should be continually refined. Finally, given
the interdisciplinary nature of HC-HIV acquisition analyses, collaborative efforts between
specialists of various disciplines are urgently needed.
Moving from data to policy regarding HC and HIV acquisition requires clearly framing the
pertinent question(s) that can be answered with robust methods that assess necessarily
imperfect data. Randomized trial data do not currently exist and animal model results have
not always had clear implications for human female reproductive biology. Discussions about
the feasibility of a randomized trial in this area are ongoing, but results would not be
available for at least 5 years. In this vein, observational analyses from ongoing and planned
epidemiologic studies, performed with robust analytic techniques and applied to high quality
datasets, may be the most efficient and cost-effective means to contribute further
understanding of this problem, especially in the near-term. Policy guidelines must consider
the important contributions of HC to reducing maternal and infant morbidity and mortality
and balance this with a robust estimation of the magnitude of how specific HC methods may
or may not increase HIV acquisition risk. Resolution of this question is a high priority on the
global health agenda, for women at risk of HIV, their partners, contraceptive and HIV care
providers, women's health advocates, and the global health community.
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Figure 1. Factors that may confound or mediate the relationship between depot-
medroxyprogesterone acetate (DMPA) use and HIV acquisition
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Figure 2. Conceptual model to illustrate the difference in total and direct effects for a simplified
potential relationship of hormonal contraceptive use, condom use, and HIV acquisition*
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